Severe acute pancreatitis(SAP),which is the most serious type of this disorder,is associated with high morbidity and mortality. SAP runs a biphasic course. During the first 1-2 wk,a pro-inflammatory response results i...Severe acute pancreatitis(SAP),which is the most serious type of this disorder,is associated with high morbidity and mortality. SAP runs a biphasic course. During the first 1-2 wk,a pro-inflammatory response results in systemic inflammatory response syndrome(SIRS). If the SIRS is severe,it can lead to early multisystem organ failure(MOF). After the first 1-2 wk,a transition from a pro-inflammatory response to an anti-inflammatory response occurs;during this transition,the patient is at risk for intestinal flora translocation and the development of secondary infection of the necrotic tissue,which can result in sepsis and late MOF. Many recommendations have been made regarding SAP management and its complications. However,despite the reduction in overall mortality in the last decade,SAP is still associated with high mortality. In the majority of cases,sterile necrosis should be managed conservatively,whereas in infected necrotizing pancreatitis,the infected non-vital solid tissue should be removed to control the sepsis. Intervention should be delayed for as long as possible to allow better demarcation and liquefaction of the necrosis. Currently,the step-up approach(delay,drain,and debride) may be considered as the reference standard intervention for this disorder.展开更多
目的评估联合抗炎和免疫刺激治疗严重脓毒症方法的有效性。方法本研究采用多中心、前瞻、随机、对照方法。共433例患者进入本研究。进入 ICU 内严重脓毒症(Marshall 评分5～20)的患者入选,随机分为对照组:常规治疗;治疗组1(第1阶段):常...目的评估联合抗炎和免疫刺激治疗严重脓毒症方法的有效性。方法本研究采用多中心、前瞻、随机、对照方法。共433例患者进入本研究。进入 ICU 内严重脓毒症(Marshall 评分5～20)的患者入选,随机分为对照组:常规治疗;治疗组1(第1阶段):常规治疗+乌司他丁30万 U/日,α1胸腺肽(迈普新)1.6 mg/d,连续7 d;治疗组2(第2阶段):常规治疗+乌司他丁60万 U/日,迈普新3.2 mg/日,连续7 d,进行28 d 和90 d 预后等疗效评估。结果第1阶段91例,治疗组(治疗组1)与对照组28 d 预后等各项疗效评估指标差异均无统计学意义。第2阶段342例,治疗组(治疗组2)与对照组相比(意向治疗分析),28 d 病死率为25.1%vs 38.3%(P=0.0088),90 d 病死率为37.1%vs 52.1%(P=0.0054),28 d APACHEⅡ评分12.7±9.4 vs 14.3±9.2(P=0.0384),28 d 单核细胞 HLA-DR/CD14+(51.7±26.5)%vs(40.1±22.0)%(P=0.0092)。其他疗效评估指标,如 ICU内治疗天数、呼吸机使用天数、抗生素使用时间等,两组差异无统计学意义。结论本研究治疗方案能够明显改善严重脓毒症患者28 d 和90 d 预后,具有积极推广价值;治疗的有效性具有剂量依赖性,最佳剂量有待进一步探讨。展开更多
目的回顾性研究乳酸清除率与重度脓毒症患者预后的相关性。方法收集247例重度脓毒症患者入ICU后的APACHEⅡ评分、脓毒症休克发生率、入ICU 12 h后乳酸清除率及患者转归。分别将病例分成存活组和死亡组,高乳酸清除率组和低乳酸清除率组,...目的回顾性研究乳酸清除率与重度脓毒症患者预后的相关性。方法收集247例重度脓毒症患者入ICU后的APACHEⅡ评分、脓毒症休克发生率、入ICU 12 h后乳酸清除率及患者转归。分别将病例分成存活组和死亡组,高乳酸清除率组和低乳酸清除率组,比较其差异的统计学意义。结果各组年龄、性别、APACHEⅡ评分和初始血乳酸浓度比较差异均无统计学意义(P＞0．05)。存活组脓毒症休克发生率明显低于死亡组(31．03% vs 83．33%,P＜0．01),乳酸清除率明显高于死亡组[(31．86±16．34)% vs(14．77±10．35)%,P＜0．01]；高乳酸清除率组脓毒症休克发生率、病死率均明显低于低乳酸清除率组(29．45% vs 90．48%,30．67% vs 85．71%,P均＜0．01)。APACHEⅡ评分与病死率无相关性。结论乳酸清除率可用于早期评估重度脓毒症患者的预后转归。展开更多
文摘Severe acute pancreatitis(SAP),which is the most serious type of this disorder,is associated with high morbidity and mortality. SAP runs a biphasic course. During the first 1-2 wk,a pro-inflammatory response results in systemic inflammatory response syndrome(SIRS). If the SIRS is severe,it can lead to early multisystem organ failure(MOF). After the first 1-2 wk,a transition from a pro-inflammatory response to an anti-inflammatory response occurs;during this transition,the patient is at risk for intestinal flora translocation and the development of secondary infection of the necrotic tissue,which can result in sepsis and late MOF. Many recommendations have been made regarding SAP management and its complications. However,despite the reduction in overall mortality in the last decade,SAP is still associated with high mortality. In the majority of cases,sterile necrosis should be managed conservatively,whereas in infected necrotizing pancreatitis,the infected non-vital solid tissue should be removed to control the sepsis. Intervention should be delayed for as long as possible to allow better demarcation and liquefaction of the necrosis. Currently,the step-up approach(delay,drain,and debride) may be considered as the reference standard intervention for this disorder.
文摘目的评估联合抗炎和免疫刺激治疗严重脓毒症方法的有效性。方法本研究采用多中心、前瞻、随机、对照方法。共433例患者进入本研究。进入 ICU 内严重脓毒症(Marshall 评分5～20)的患者入选,随机分为对照组:常规治疗;治疗组1(第1阶段):常规治疗+乌司他丁30万 U/日,α1胸腺肽(迈普新)1.6 mg/d,连续7 d;治疗组2(第2阶段):常规治疗+乌司他丁60万 U/日,迈普新3.2 mg/日,连续7 d,进行28 d 和90 d 预后等疗效评估。结果第1阶段91例,治疗组(治疗组1)与对照组28 d 预后等各项疗效评估指标差异均无统计学意义。第2阶段342例,治疗组(治疗组2)与对照组相比(意向治疗分析),28 d 病死率为25.1%vs 38.3%(P=0.0088),90 d 病死率为37.1%vs 52.1%(P=0.0054),28 d APACHEⅡ评分12.7±9.4 vs 14.3±9.2(P=0.0384),28 d 单核细胞 HLA-DR/CD14+(51.7±26.5)%vs(40.1±22.0)%(P=0.0092)。其他疗效评估指标,如 ICU内治疗天数、呼吸机使用天数、抗生素使用时间等,两组差异无统计学意义。结论本研究治疗方案能够明显改善严重脓毒症患者28 d 和90 d 预后,具有积极推广价值;治疗的有效性具有剂量依赖性,最佳剂量有待进一步探讨。
文摘目的回顾性研究乳酸清除率与重度脓毒症患者预后的相关性。方法收集247例重度脓毒症患者入ICU后的APACHEⅡ评分、脓毒症休克发生率、入ICU 12 h后乳酸清除率及患者转归。分别将病例分成存活组和死亡组,高乳酸清除率组和低乳酸清除率组,比较其差异的统计学意义。结果各组年龄、性别、APACHEⅡ评分和初始血乳酸浓度比较差异均无统计学意义(P＞0．05)。存活组脓毒症休克发生率明显低于死亡组(31．03% vs 83．33%,P＜0．01),乳酸清除率明显高于死亡组[(31．86±16．34)% vs(14．77±10．35)%,P＜0．01]；高乳酸清除率组脓毒症休克发生率、病死率均明显低于低乳酸清除率组(29．45% vs 90．48%,30．67% vs 85．71%,P均＜0．01)。APACHEⅡ评分与病死率无相关性。结论乳酸清除率可用于早期评估重度脓毒症患者的预后转归。
